Nasdaq

Solid Biosciences Doses First Participant in First-in-Class Phase 1b FALCON Trial Evaluating SGT-212 Dual-Route Gene Therapy for the Treatment of Friedreich’s Ataxia

CHARLESTOWN, Mass., Jan. 12, 2026 (GLOBE NEWSWIRE) -- Solid Biosciences Inc. (Nasdaq: SLDB) (the “Company” or “Solid”), a life sciences company developing precision genetic medicines for neuromuscular ...
MarketWatch

Congruence Announces First Dosing in Phase 1/1b Clinical Trial of CGX-926, a First-in-Class Oral MC4R Corrector for Genetic Obesity

The MarketWatch News Department was not involved in the creation of this content. MONTREAL, March 19, 2026 /PRNewswire/ -- Congruence Therapeutics today announced that the first participant has been ...
The Manila Times

JJP Biologics Announces Positive Interim Phase 1b Data for Nebaprubart (JJP-1212), an Anti-CD89 Antagonist, in Linear IgA Disease (LAD)

Favorable safety and tolerability profile, with rapid onset of clinical activity and therapeutic effects observed in patients with LADData support the start of a Phase 1b clinical trial in rheumatoid ...
Morningstar

Drug Farm to Present Ophthalmologic and CNS Findings from Phase 1b Study of First-in-Class ALPK1 Inhibitor DF-003 in ROSAH Syndrome at ARVO 2026

Drug Farm to Present Ophthalmologic and CNS Findings from Phase 1b Study of First-in-Class ALPK1 Inhibitor DF-003 in ROSAH Syndrome at ARVO 2026 Drug Farm today announced ophthalmologic and central ...
The Manila Times

Therini Bio Doses First Patients in Phase 1b Trial of Novel Anti-Inflammatory Therapy, THN391, for Diabetic Macular Edema

Company also advances fibrin/VEGF bispecific antibody THN622, a potential new standard of care for retinal neurodegeneration ...
Morningstar

Drug Farm to Present Positive Phase 1b Data for First-in-Class ALPK1 Inhibitor DF-003 in ROSAH Syndrome at IMMUNOLOGY2026™

Drug Farm to Present Positive Phase 1b Data for First-in-Class ALPK1 Inhibitor DF-003 in ROSAH Syndrome at IMMUNOLOGY2026™ Drug Farm today announced that preliminary immunologic and clinical results ...